Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis

Archives of Neurology

Volumn 68, Issue 4, 2011, Pages 437-444

  Yeh, E Ann ^a,b   Waubant, Emmanuelle ^e   Krupp, Lauren B ^d   Ness, Jayne ^f   Chitnis, Tanuja ^g   Kuntz, Nancy ^h   Ramanathan, Murali ^a,b,c   Belman, Anita ^d   Chabas, Dorothee ^e   Gorman, Mark P ^g   Rodriguez, Moses ⁱ   Rinker II, John Robert ^f   Weinstock Guttman, Bianca ^a,b  

^a CHILDREN S HOSPITAL OF BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UCSF Multiple Sclerosis Center   (United States)

^f UAB Center for Pediatric Onset Demyelinating Disease   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB;

ARTICLE; CHILD; CLINICAL OBSERVATION; DISEASE COURSE; DISEASE MODIFYING THERAPY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; MULTIPLE SCLEROSIS; ONSET AGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THERAPY; UNITED STATES;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES;

EID: 79953848705     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.325     Document Type: Article

References (30)

1. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D; University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59(7):1006-1010.
2. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the northeastern United States. Mult Scler. 2009;15(5):627-631.
3. Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997;3(1):43-46. (Pubitemid 27234861)
4. Renoux C, Vukusic S, Mikaeloff Y, et al; Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603-2613. (Pubitemid 46961005)
5. Hauser SL, Waubant E, Arnold DL, et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7):676-688. (Pubitemid 351240747)
6. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395-400. (Pubitemid 351499869)
7. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A. 2004;101(23):8705-8708. (Pubitemid 38745835)
8. Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008;65(8):1044-1051.
9. Then Bergh F, Kümpfel T, Schumann E, et al. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis: reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol. 2006;6:19.
10. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B; Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet. 1997;349(9052):589-593.
11. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol. 2008;255(suppl 1):44-50. (Pubitemid 351341872)
12. Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%? Neurology. 2009;73(12):984-990.
13. Waubant E, Hietpas J, Stewart T, et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001;32(4):211-213. (Pubitemid 32895904)
14. Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472-476. (Pubitemid 43739870)
15. Pohl D, Rostasy K, Gärtner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64(5):888-890. (Pubitemid 40316332)
16. Mikaeloff Y, Moreau T, Debouverie M, et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr. 2001;139(3):443-446. (Pubitemid 32889524)
17. Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67(3):511-513. (Pubitemid 44214986)
18. Ghezzi A, Amato MP, Capobianco M, et al; Immunomodulatory Treatment of Early Onset MS Group. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005;11(4):420-424.
19. Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003;34(3):120-126. (Pubitemid 36994400)
20. Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol. 2009;13(1):67-71.
21. Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008;65(12):1655-1658.
22. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009;72(24):2076-2082.
23. Krupp LB, Banwell B, Tenembaum S; International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68(16)(suppl 2):S7-S12.
24. National Institutes of Health. NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research, amended October 2001. http://grants.nih.gov/grants/funding/women-min/guidelines-amended-10-2001.htm. Accessed September 1, 2010.
25. Río J, Nos C, Tintoré M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006;59(2):344-352.
26. Gauthier SA, Glanz BI, Mandel M, et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci. 2009;284(1-2):116-119.
27. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63(11):2039-2045. (Pubitemid 39636249)
28. Weinstock-Guttman B, Ramanathan M, Hashmi K, et al. Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology. 2010;74(7):538-544.
29. Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005;62(11):1681-1683. (Pubitemid 41626662)
30. Cohen BA, Khan O, Jeffery DR, et al. Identifying and treating patients with suboptimal responses. Neurology. 2004;63(12)(suppl 6):S33-S40. (Pubitemid 40019277)